Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a ...
Cytospire Therapeutics raises £61M in Series A funding to advance innovative cancer immunotherapy targeting gamma delta T ...
Cytospire Therapeutics has secured $83 million in Series A funding to progress its first-in-class pan-gamma delta T cell engagers into clinical trials for cancer. The approach aims to overcome safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results